Steeghs, Elisabeth M. P.
Kroeze, Leonie I.
Tops, Bastiaan B. J.
van Kempen, Leon C.
ter Elst, Arja
Kastner-van Raaij, Annemiek W. M.
Hendriks-Cornelissen, Sandra J. B.
Hermsen, Mandy J. W.
Jansen, Erik A. M.
Nederlof, Petra M.
Schuuring, Ed
Ligtenberg, Marjolijn J. L.
Eijkelenboom, Astrid
Funding for this research was provided by:
ZonMw (846001001)
Article History
Received: 21 October 2019
Accepted: 25 March 2020
First Online: 7 April 2020
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Local Ethical Committee of the Radboudumc (CMO 2016–2967). Informed consent was not applicable, as the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects. The Local Ethical Committee of the Radboudumc approved the waiver of consent. Data from patients who objected against the use of their data for scientific research were excluded from the study.
: Not applicable.
: The authors declare that they have no conflict of interest.BBJT is a member of the BMC Cancer editorial board, but has not played any role in editorial decisions made regarding this manuscript. Outside the submitted work MJLL has relations with AstraZeneca, Bayer, Bristol-Myers Squibb, Illumina, Janssen pharmaceuticals, Merck, and Nimagen; outside the submitted work LCvK has relations with Janssen pharmaceuticals, Bristol-Myers Squib, Merck, nanoString, and is an advisor for Guidepoint; outside the submitted work ES has relations with AstraZeneca, Roche, Pfizer, Novartis, Bayer, BMS, BioCartis, Illumina, Agena Bioscience, CC Diagnostics, Janssen Cilag (Johnson&Johnson), Diaceutics, Bio-Rad, Abbott, Boehringer Ingelheim, Promega.